Benign Prostatic Hyperplasia (BPH) Market Insights, Epidemiology and Market Forecast- 2027

Albany, NY -- (SBWire) -- 10/19/2018 --DelveInsight has announced the addition of the "Benign Prostatic Hyperplasia (BPH) Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of BPH for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Benign Prostatic Hyperplasia forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Benign prostatic hyperplasia (BPH) refers to the proliferation of epithelial and smooth muscle cells within the transition zone of the prostate. The term has been used to describe a constellation of voiding symptoms that occur in ageing men. The symptoms are generally referred to as obstructive in nature, as the hyperplastic tissue leads to a narrowing of the prostatic urethra. Such symptoms include: decreased force of stream, hesitancy, straining, incomplete bladder emptying, and nocturia. Irritative symptoms are also associated with BPH and include urinary frequency, urgency, and occasionally dysuria. Benign prostatic hyperplasia (BPH) is one of the most common urological diseases among men; since this disease is related to prostate glands (which are exclusively found in males), BPH doesn't affect females.

The histologic prevalence of BPH is approximately 10% for men in their 30s, 20% for men in their 40s, reaches 50% to 60% for men in their 60s, and is 80% to 90% for men in their 70s and 80s. The prevalence of BPH increases after the age of 40 years, with a prevalence of 8%–60% at age 90 years. According to US National Library of Medicine NIH, Parsons JK et al (2014), the incidence and prevalence of BPH have increased rapidly. The incidence as well as prevalence rate of BPH increases linearly with age and reaches its maximum at the age of 79 years.

BPH, the actual hyperplasia of the prostate gland, develops as a strictly age-related phenomenon in nearly all men, starting at approximately 40 years of age. In fact, the histologic prevalence of BPH, which has been examined in several autopsy studies around the world, is approximately 10% for men in their 30s, 20% for men in their 40s, reaches 50% to 60% for men in their 60s, and is 80% to 90% for men in their 70s and 80s.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Benign Prostatic Hyperplasia Drug Companies
1. Merck
2. GlaxoSmithKline
3. Abbvie
4. Pfizer
And many others

Drugs covered

1. Proscar
2. Avodart
3. Jalyn
4. Hytrin
And many others

Report Scope

The report covers a descriptive overview of the Benign Prostatic Hyperplasia, explaining its causes and currently available therapies. Comprehensive insight has been provided Benign Prostatic Hyperplasia into the epidemiology of the Benign Prostatic Hyperplasia and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Benign Prostatic Hyperplasia are provided, along with assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Benign Prostatic Hyperplasia market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Benign Prostatic Hyperplasia market.